CSPC Pharmaceutical Group Limited CSPCY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.78B | 933.53M | 862.59M | 924.59M | 865.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.78B | 933.53M | 862.59M | 924.59M | 865.55M |
| Cost of Revenue | 328.71M | 317.23M | 296.99M | 318.40M | 311.67M |
| Gross Profit | 1.45B | 616.30M | 565.61M | 606.19M | 553.88M |
| SG&A Expenses | 277.27M | 273.15M | 263.95M | 274.78M | 216.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 845.03M | 792.92M | 789.99M | 803.09M | 718.60M |
| Operating Income | 937.37M | 140.61M | 72.61M | 121.50M | 146.94M |
| Income Before Tax | 939.82M | 163.70M | 71.32M | 165.54M | 182.77M |
| Income Tax Expenses | 121.34M | 35.12M | 23.37M | 31.08M | 33.52M |
| Earnings from Continuing Operations | 818.48M | 128.58M | 47.96M | 134.46M | 149.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -49.27M | -4.43M | 4.34M | 160.40K | -1.30M |
| Net Income | 769.21M | 124.15M | 52.30M | 134.62M | 147.96M |
| EBIT | 937.37M | 140.61M | 72.61M | 121.50M | 146.94M |
| EBITDA | 980.30M | 182.10M | 113.14M | 159.40M | 188.41M |
| EPS Basic | 0.07 | 0.01 | 0.00 | 0.01 | 0.01 |
| Normalized Basic EPS | 0.05 | 0.01 | 0.00 | 0.01 | -- |
| EPS Diluted | 0.07 | 0.01 | 0.00 | 0.01 | 0.01 |
| Normalized Diluted EPS | 0.05 | 0.01 | 0.00 | 0.01 | -- |
| Average Basic Shares Outstanding | 11.40B | 11.40B | 11.40B | 11.43B | 11.42B |
| Average Diluted Shares Outstanding | 11.44B | 11.40B | 11.40B | 11.43B | 11.42B |
| Dividend Per Share | 0.02 | -- | 0.02 | 0.00 | 0.02 |
| Payout Ratio | -- | -- | -- | -- | -- |